GO:0031707 endothelin A receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031707 endothelin A receptor binding is a molecular function defined as binding to an endothelin A receptor (EDNRA), a G-protein-coupled receptor.
• Endothelin-1 (EDN1) is the principal endogenous ligand for EDNRA, and this interaction drives vasoconstriction, cell proliferation, and pain signaling.
• EDNRA binding is implicated in chronic kidney disease, pulmonary arterial hypertension, vascular pain, and multiple cancers.
• Loss-of-function mutations in EDNRA cause Oro-Oto-Cardiac syndrome, linking the receptor to craniofacial and cardiac development.
• EDNRA internalization and cross-talk with endothelin B receptor (EDNRB) regulate the duration and intensity of signaling.
• CRISPR-based knockout, point-mutation, and knock-in models are essential to dissect EDNRA ligand binding and downstream effects.
Description
Endothelin A receptor binding (GO:0031707) is a molecular function that describes the physical interaction between a ligand and the endothelin A receptor (EDNRA), a member of the G-protein-coupled receptor superfamily. This binding event is the first step in a signaling cascade that regulates vascular tone, cell proliferation, and pain perception. The endothelin system is one of the most potent vasoconstrictor pathways in humans, and its dysregulation is linked to a wide range of diseases, including chronic kidney disease, pulmonary arterial hypertension, and cancer. Researchers study this term to understand how extracellular signals are translated into intracellular responses and to develop targeted therapies that block or modulate EDNRA activity. The specificity of ligand-receptor binding is critical: endothelin-1 (EDN1) binds EDNRA with high affinity, while endothelin-3 (EDN3) shows lower affinity, and this selectivity determines downstream effects. Understanding the molecular details of GO:0031707 is therefore essential for both basic biology and translational medicine.
endothelin A receptor binding At A Glance
| GO ID | GO:0031707 |
|---|---|
| GO term | endothelin A receptor binding |
| Ontology | molecular_function |
| Synonym | endothelin-1 receptor binding, endothelin A receptor ligand |
| Definition | Binding to an endothelin A receptor. |
| Major function | Mediates ligand-receptor interaction for endothelin signaling, affecting vasoconstriction, proliferation, and pain. |
| Major ligands | Endothelin-1 (EDN1), endothelin-2 (EDN2), endothelin-3 (EDN3). |
| Receptor | Endothelin A receptor (EDNRA), a G-protein-coupled receptor. |
| Related diseases | Chronic kidney disease, pulmonary arterial hypertension, Oro-Oto-Cardiac syndrome, prostate cancer. |
What Is GO:0031707?
In simple terms, GO:0031707 endothelin A receptor binding is the function of a molecule (typically a peptide ligand such as endothelin-1) physically attaching to the endothelin A receptor (EDNRA). This binding is non-covalent and highly specific, initiating conformational changes in the receptor that lead to intracellular signaling. The term is a molecular function in the Gene Ontology, and it is distinct from receptor activity itself; it describes the ligand's ability to bind, not the receptor's downstream actions.
Why Is endothelin A receptor binding Important in Cell Biology?
GO:0031707 is important because it represents the initial molecular event that triggers one of the most powerful vasoconstrictor and mitogenic pathways in human physiology. Dysregulation of endothelin A receptor binding contributes to hypertension, chronic kidney disease, pulmonary arterial hypertension, and cancer progression. Moreover, EDNRA is a validated drug target: selective antagonists such as ZD4054 have shown promise in metastatic castration-resistant prostate cancer. Understanding the binding mechanism at atomic resolution enables the design of improved antibodies and small molecules with better affinity and serum persistence. In developmental biology, loss of EDNRA function causes Oro-Oto-Cardiac syndrome, highlighting its role in craniofacial and cardiac morphogenesis. Thus, studying this term bridges basic receptor biology and clinical applications.
• Endothelin A receptor binding initiates vasoconstriction, a key process in blood pressure regulation.
• It mediates pain signaling through an endothelial-neural axis, relevant to vascular pain.
• Dysregulated binding contributes to chronic kidney disease progression.
• EDNRA binding promotes pulmonary arterial smooth muscle cell proliferation in pulmonary hypertension.
• Loss-of-function mutations in EDNRA cause Oro-Oto-Cardiac syndrome, affecting development.
• EDNRA is overexpressed in several cancers, including prostate cancer, making it a therapeutic target.
• Receptor internalization after binding regulates signal duration and receptor recycling.
• Cross-talk between EDNRA and EDNRB modulates overall endothelin signaling.
• Engineered antibodies with improved EDNRA binding affinity show antitumor potency.
• Selective EDNRA antagonism is being explored to improve clinical outcomes in kidney disease.
What Happens During endothelin A receptor binding?
Ligand recognition and initial binding
In simple terms: The ligand, usually endothelin-1, finds and attaches to the endothelin A receptor on the cell surface.
Endothelin-1 (EDN1) is a 21-amino-acid peptide with a bicyclic structure that confers high affinity for EDNRA. The binding interface involves the N-terminal region of EDN1 and the extracellular loops of EDNRA, leading to a conformational change in the receptor. This initial recognition is highly specific; EDN3 binds EDNRA with lower affinity, which contributes to differential signaling.
Receptor activation and G-protein coupling
In simple terms: Once the ligand is bound, the receptor changes shape and activates G-proteins inside the cell.
Ligand binding stabilizes an active conformation of EDNRA that promotes guanine nucleotide exchange on Gq/11 proteins. This leads to phospholipase C activation, IP3 production, and calcium release, ultimately causing smooth muscle contraction. The activated receptor can also couple to other G-proteins, but Gq/11 is the primary mediator of vasoconstriction.
Internalization and trafficking
In simple terms: After signaling, the receptor is pulled inside the cell to be recycled or degraded.
Agonist-bound EDNRA undergoes rapid internalization via clathrin-coated pits. This process is regulated by phosphorylation of the receptor's C-terminal tail and recruitment of beta-arrestins. Internalization serves to terminate signaling and to sort the receptor for either recycling back to the plasma membrane or degradation in lysosomes.
Cross-talk with endothelin B receptor
In simple terms: The endothelin A receptor communicates with another receptor, endothelin B, to fine-tune the response.
EDNRA and EDNRB can form heterodimers or influence each other's signaling through shared ligands and downstream pathways. For example, EDNRB activation can enhance EDNRA-mediated vasoconstriction in some vascular beds, while in others it promotes vasodilation via nitric oxide. This cross-talk adds complexity to endothelin biology and is a target for therapeutic modulation.
Key Genes Involved in GO:0031707 endothelin A receptor binding
The following genes and proteins are central to endothelin A receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EDN1 | Primary ligand for EDNRA; potent vasoconstrictor | Knockout causes hypertension and developmental defects |
| EDN2 | Ligand with high affinity for EDNRA | Less studied; potential role in ovulation and cardiovascular function |
| EDN3 | Ligand with lower affinity for EDNRA; high affinity for EDNRB | Involved in neural crest development |
| EDNRA | G-protein-coupled receptor that binds endothelins | Mutations cause Oro-Oto-Cardiac syndrome; drug target |
| EDNRB | Related receptor that cross-talks with EDNRA | Modulates endothelin signaling and vascular tone |
| GNAQ | G-protein alpha subunit that couples to EDNRA | Mediates downstream calcium signaling |
| GNA11 | G-protein alpha subunit that couples to EDNRA | Mediates downstream calcium signaling |
| ARRB1 | Beta-arrestin 1; involved in EDNRA internalization | Regulates receptor trafficking |
| ARRB2 | Beta-arrestin 2; involved in EDNRA internalization | Regulates receptor trafficking |
| ECE1 | Endothelin-converting enzyme 1; generates mature EDN1 | Required for EDN1 activation |
| ECE2 | Endothelin-converting enzyme 2; generates mature EDN1 | Required for EDN1 activation |
| NPPB | BNP; can modulate endothelin signaling | Biomarker in heart failure |
| AGT | Angiotensinogen; interacts with endothelin pathway | Hypertension research |
| REN | Renin; part of renin-angiotensin system | Hypertension research |
| ACE | Angiotensin-converting enzyme | Hypertension research |
| AGTR1 | Angiotensin II receptor type 1 | Cross-talk with endothelin signaling |
| NOS3 | Endothelial nitric oxide synthase; counteracts EDNRA vasoconstriction | Vascular tone regulation |
| PTGS2 | COX-2; induced by endothelin signaling | Inflammation and pain |
How Is endothelin A receptor binding Regulated?
Endothelin A receptor binding is regulated at multiple levels. Ligand availability is controlled by endothelin-converting enzymes (ECE1, ECE2) that cleave big endothelin-1 to the mature peptide. Receptor expression is modulated by transcription factors and microRNAs in response to hypoxia and inflammation. Post-translational modifications, such as persulfidation of EDNRA by hydrogen sulfide, can inhibit receptor activity and downstream proliferation. Additionally, beta-arrestin-mediated internalization and recycling determine the duration of signaling. Cross-talk with EDNRB and other G-protein-coupled receptors further fine-tunes the response.
endothelin A receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EDNRA | Chronic kidney disease | Conditional knockout mouse in renal tubules |
| EDNRA | Pulmonary arterial hypertension | Smooth muscle cell-specific knockout or point-mutation knock-in |
| EDNRA | Prostate cancer | Xenograft with EDNRA overexpression or knockout |
| EDNRA | Oro-Oto-Cardiac syndrome | Patient-derived iPSCs with EDNRA loss-of-function mutation |
| EDN1 | Vascular pain | Neuron-specific EDN1 knockout or knock-in |
Chronic kidney disease and hypertension
Endothelin A receptor binding contributes to renal vasoconstriction, inflammation, and fibrosis, driving chronic kidney disease progression. Selective EDNRA antagonism is being investigated to improve clinical outcomes in patients with chronic kidney disease. In hypertension, excessive EDNRA activation leads to increased vascular tone and sodium retention.
Pulmonary arterial hypertension
In pulmonary arterial hypertension, EDNRA binding promotes pulmonary arterial smooth muscle cell proliferation and vasoconstriction. Endogenous hydrogen sulfide can persulfidate EDNRA, inhibiting its activity and attenuating proliferation, suggesting a protective mechanism.
Cancer
EDNRA is overexpressed in several cancers, including prostate cancer, where it promotes cell survival and proliferation. Engineered antibodies with improved EDNRA binding affinity exhibit antitumor potency, and selective antagonists like ZD4054 have shown activity in metastatic castration-resistant prostate cancer.
Vascular pain and Oro-Oto-Cardiac syndrome
Neuronal EDNRA mediates experimental and clinical vascular pain through an endothelial-neural axis. Loss-of-function mutations in EDNRA cause Oro-Oto-Cardiac syndrome, characterized by craniofacial, otic, and cardiac defects, highlighting its role in development.
From endothelin A receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does EDNRA binding mediate vasoconstriction? | EDNRA knockout mouse or smooth muscle cell-specific knockout |
| What is the effect of a specific point mutation in EDNRA on ligand affinity? | Point-mutation knock-in via CRISPR in cell lines |
| How does EDNRA internalization affect signaling duration? | Knock-in of tagged EDNRA (e.g., GFP) for live imaging |
| Can overexpression of EDNRA drive tumor growth? | Xenograft models with EDNRA overexpression |
| What is the role of EDNRA in pain signaling? | Neuron-specific knockout or knock-in of EDNRA |
| Does EDNRA cross-talk with EDNRB? | Double knockout or knock-in of both receptors |
How to Study the endothelin A receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity (Kd) and Bmax of ligand-receptor interaction | Characterizing EDNRA binding in cell membranes |
| Surface plasmon resonance | Real-time association and dissociation kinetics | Antibody or small molecule affinity ranking |
| CRISPR knockout screen | Genes required for EDNRA binding or signaling | Identifying novel regulators |
| Live-cell imaging | Receptor internalization and trafficking | Studying beta-arrestin recruitment |
| AP-MS | Protein-protein interactions | Mapping EDNRA interactome |
| Phosphoproteomics | Signaling pathways activated | Downstream kinase identification |
| Calcium flux assay | Gq-mediated calcium release | Functional EDNRA activation |
| ELISA | Ligand or receptor quantification | Measuring EDN1 levels in disease models |
Binding assays
Radioligand binding assays using 125I-labeled endothelin-1 are the gold standard to measure EDNRA binding affinity and kinetics. Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) provide real-time kinetic and thermodynamic data.
CRISPR-based genetic screens
Genome-wide CRISPR knockout screens can identify genes that modulate EDNRA binding and downstream signaling. Focused screens targeting GPCRs and signaling components can reveal novel regulators.
Imaging and trafficking
Live-cell imaging of fluorescently tagged EDNRA (e.g., GFP or pH-sensitive probes) allows visualization of internalization and recycling. Total internal reflection fluorescence (TIRF) microscopy can capture single-molecule binding events.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry (AP-MS) can identify proteins that interact with EDNRA upon ligand binding. Phosphoproteomics can map signaling events downstream of EDNRA activation.
How CRISPR Can Be Used to Study GO:0031707 endothelin A receptor binding
Knockout
CRISPR knockout of EDNRA in cell lines or animal models abolishes endothelin A receptor binding, allowing researchers to study loss-of-function phenotypes such as reduced vasoconstriction and altered development. Knockout of EDN1 or ECE1 similarly eliminates ligand availability.
Point Mutation
Point mutations in EDNRA can mimic naturally occurring variants, such as those found in Oro-Oto-Cardiac syndrome, to dissect the impact on ligand binding affinity and downstream signaling. CRISPR base editors or homology-directed repair (HDR) can introduce precise mutations.
Knock-in
Knock-in of tagged EDNRA (e.g., GFP, HA, or luciferase) enables real-time tracking of receptor localization, internalization, and recycling. Knock-in of reporter genes under the EDNRA promoter can monitor expression dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of EDNRA can model receptor overexpression in cancers and cardiovascular diseases. Overexpression studies help identify downstream oncogenic pathways.
How EDITGENE Supports endothelin A receptor binding Research
Researchers studying endothelin A receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand binding, receptor activation, or downstream pathology. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for endothelin A receptor binding research.
Frequently Asked Questions About endothelin A receptor binding
What is GO:0031707 endothelin A receptor binding?
GO:0031707 is a Gene Ontology molecular function term defined as binding to an endothelin A receptor (EDNRA), a G-protein-coupled receptor.
What genes are involved in endothelin A receptor binding?
Key genes include EDN1 (ligand), EDNRA (receptor), ECE1 (ligand processing), and GNAQ/GNA11 (downstream G-proteins).
What diseases are associated with endothelin A receptor binding?
It is linked to chronic kidney disease, pulmonary arterial hypertension, prostate cancer, vascular pain, and Oro-Oto-Cardiac syndrome.
How is endothelin A receptor binding studied?
Common methods include radioligand binding assays, surface plasmon resonance, CRISPR screens, live-cell imaging, and proteomics.
What is the role of endothelin-1 in endothelin A receptor binding?
Endothelin-1 (EDN1) is the primary endogenous ligand that binds EDNRA with high affinity, triggering vasoconstriction and cell proliferation.
Can CRISPR be used to study endothelin A receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect EDNRA function and ligand interactions.
What is the difference between endothelin A and B receptors?
EDNRA primarily mediates vasoconstriction and proliferation, while EDNRB can promote vasodilation and clearance of endothelin; they also cross-talk.
What are the symptoms of Oro-Oto-Cardiac syndrome?
Oro-Oto-Cardiac syndrome, caused by EDNRA loss-of-function, involves craniofacial, otic, and cardiac abnormalities.
Are there drugs targeting endothelin A receptor binding?
Yes, selective EDNRA antagonists such as ZD4054 and engineered antibodies are in development for cancer and kidney disease.
How does hydrogen sulfide affect endothelin A receptor binding?
Hydrogen sulfide can persulfidate EDNRA, inhibiting its activity and reducing pulmonary arterial smooth muscle cell proliferation.
Conclusion
GO:0031707 endothelin A receptor binding is a fundamental molecular function that initiates a powerful signaling cascade with broad physiological and pathological implications. From vasoconstriction and pain to cancer and developmental syndromes, the interaction between endothelins and EDNRA is a critical node for therapeutic intervention. Advances in CRISPR-based models and high-throughput screening are accelerating our understanding of this term and enabling the development of more precise drugs. Continued research into the structural and regulatory mechanisms of EDNRA binding will likely yield new treatments for cardiovascular, renal, and oncological diseases.
References
- 1. Moedt E et al.. 2025. Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.. Nephrol Dial Transplant 40(Supplement_1):i37-i46 PMID: 39907539
- 2. Rapoport RM et al.. 2011. Endothelin(A)-endothelin(B) receptor cross-talk and endothelin receptor binding.. J Pharm Pharmacol 63(11):1373-7 PMID: 21988418
- 3. Jiang ZJ et al.. 2025. Neuronal Endothelin a Receptor Mediates Experimental and Clinical Vascular Pain through an Endothelial-Neural Axis.. Adv Sci (Weinh) 12(42):e12375 PMID: 40810652
- 4. Zhang Y et al.. 2025. Endogenous hydrogen sulfide persulfidates endothelin type A receptor to inhibit pulmonary arterial smooth muscle cell proliferation.. Redox Biol 80:103493 PMID: 39823888
- 5. Pritchard AB et al.. 2020. Loss-of-function of Endothelin receptor type A results in Oro-Oto-Cardiac syndrome.. Am J Med Genet A 182(5):1104-1116 PMID: 32133772
- 6. Wang J et al.. 2000. Internalization of type-A endothelin receptor.. J Cardiovasc Pharmacol 36(5 Suppl 1):S61-5 PMID: 11078337
- 7. Ko S et al.. 2023. Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency.. Mol Pharm 20(2):1247-1255 PMID: 36563318
- 8. Warren R et al.. 2008. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.. Expert Opin Investig Drugs 17(8):1237-45 PMID: 18616419
